logo
logo

EnClear Therapies Announces $10M Series A Financing

Feb 19, 2020•over 5 years ago

Amount Raised

$10 Million

Round Type

series a

NewburyportMedical Device

Description

EnClear Therapies, a life sciences company developing device-based therapies for the treatment of neurodegenerative disease, today announced a $10 million Series A financing led by 20/20 HealthCare Partners (“20/20 HCP”), and joined by Peter Thiel, Amgen Ventures, GHS Fund (Quark Venture LP and GF Securities), Christian Angermayer’s Presight Capital and Dolby Ventures.

Company Information

Company

EnClear Therapies

Location

700 MAIN STREET

Newburyport, Massachusetts, United States

About

EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People